BioSpace News Archive

Attain, LLC, a leading management, technology, and strategy consulting firm, today announced that Cindy D’Annunzio has joined the company as a Managing Director.

This must be one of the most unique product launches of 2019: BioRebalance Nutrient Support, formulated by orthomolecular experts to fight free radical damage and oxidative stress associated with the modern lifestyle, stress, and alcohol use.

Aperture, the largest provider of credentialing services to the healthcare industry, today announced that it has hired Kymberly Eide as President.

Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) today announced eight poster presentations on lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder, will be presented at the 33rd annual meeting of the Associated Professional Sleep Societies (SLEEP 2019), June 8-12, in San Antonio.

Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, today announced that it has successfully reached the first milestone in its collaboration with Daiichi Sankyo Co., Ltd.

Puration, Inc. (USOTC: PURA) (“PURA”) today confirmed a management update to be published on the company’s website on May 30th, 2019.

Northwest Biotherapeutics (NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement agreement with Cognate BioServices, Inc., resolving past matters and providing for restart of DCVax®-Direct Production.

Corrosion of equipment can be a costly problem for the military, and with a recent five-year, $50 million task order, Battelle will continue to help the United States Marine Corps with its Corrosion Prevention and Control program.

A woman-led medical device company whose product immediately diagnoses viral and bacterial ear infections in children, and therefore reduces antibiotic overuse, has just won WomenCorporateDirectors Foundation’s (WCD) inaugural Launch Zone competition in Silicon Valley.

VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the successful industrial production of VALEDIA® (active substance TOTUM-63), the most advanced product in the VALBIOTIS portfolio